GlassScriptPhysician profile
Ashley C Amedee
NPI 1962719690
$9,350.92
in general payments reported to CMS, 2019-2025
42 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,590 · 2022: $2,133 · 2023: $1,778 · 2024: $2,216 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,628.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $905.06 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $807.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $701.89 | 2021-2025 | Jardiance, Glyxambi, Synjardy |
| Lilly USA, LLC | $660.80 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $620.02 | 2021-2025 | |
| Abbott Laboratories | $554.77 | 2022-2025 | Freestyle Libre 3, Eterna |
| Amgen INC. | $420.14 | 2021-2024 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $406.75 | 2021-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $341.20 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $325.82 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $295.00 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $287.31 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $247.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $243.83 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $229.74 | 2021-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Amedee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.